Učitavanje...
Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation
Despite the withdrawal of CB(1) antagonists, such as rimonabant, from the market and from active clinical development due to concerns about their side effect profiles, research suggests that the endocannabinoid system may play an important role in modulating nicotine’s effects. We report the combine...
Spremljeno u:
| Izdano u: | Addict Biol |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5912319/ https://ncbi.nlm.nih.gov/pubmed/28429843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/adb.12508 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|